Literature DB >> 26066896

Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.

Juul M P A van den Reek1, Wietske Kievit2, Robert Gniadecki3, Jelle J Goeman2, Jeffrey Zweegers4, Peter C M van de Kerkhof4, Marieke M B Seyger4, Elke M G J de Jong4.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26066896     DOI： 10.1038/jid.2015.171

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  10 in total

Review 1.  Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics.

Authors:  Daniel Aletaha; Josef S Smolen
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

2.  Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study.

Authors:  M Wijnands; P van Riel; M van 't Hof; F Gribnau; L van de Putte
Journal:  J Rheumatol       Date:  1991-02       Impact factor: 4.666

Review 3.  Survival probabilities (the Kaplan-Meier method).

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1998-12-05

4.  Understanding immortal time bias in observational cohort studies.

Authors:  A M-H Ho; P W Dion; C S H Ng; M K Karmakar
Journal:  Anaesthesia       Date:  2012-12-13       Impact factor: 6.955

5.  Multivariable analysis.

Authors:  Marlies Wakkee; Loes M Hollestein; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2014-05       Impact factor: 8.551

6.  'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.

Authors:  J M P A van den Reek; J Zweegers; W Kievit; M E Otero; P P M van Lümig; R J B Driessen; P M Ossenkoppele; M D Njoo; J M Mommers; M I A Koetsier; W P Arnold; B A M Sybrandy-Fleuren; A L A Kuijpers; M P M Andriessen; P C M van de Kerkhof; M M B Seyger; E M G J de Jong
Journal:  Br J Dermatol       Date:  2014-10-03       Impact factor: 9.302

7.  Drug survival of fumaric acid esters for psoriasis: a retrospective study.

Authors:  N Ismail; P Collins; S Rogers; B Kirby; A Lally
Journal:  Br J Dermatol       Date:  2014-08-06       Impact factor: 9.302

8.  The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.

Authors:  Marte Schrumpf Heiberg; Wenche Koldingsnes; Knut Mikkelsen; Erik Rødevand; Cecilie Kaufmann; Petter Mowinckel; Tore K Kvien
Journal:  Arthritis Rheum       Date:  2008-02-15

9.  Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data.

Authors:  Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2009-06-03       Impact factor: 5.156

10.  Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.

Authors:  Jieyun Yin; Hongliang Liu; Zhensheng Liu; Li-E Wang; Wei V Chen; Dakai Zhu; Christopher I Amos; Shenying Fang; Jeffrey E Lee; Qingyi Wei
Journal:  J Invest Dermatol       Date:  2014-09-22       Impact factor: 8.551
  10 in total
  18 in total

1.  Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.

Authors:  Tiago Torres; Luis Puig; Ron Vender; Jensen Yeung; José-Manuel Carrascosa; Stefano Piaserico; Paolo Gisondi; Charles Lynde; Paulo Ferreira; Pedro Mendes Bastos; Esteban Dauden; Luiz Leite; Joana Valerio; Elena Del Alcázar-Viladomiu; Eva Vilarrasa Rull; Mar Llamas-Velasco; Federico Pirro; Francesco Messina; Manfredo Bruni; Gaetano Licata; Federica Ricceri; Alessia Nidegger; Jan Hugo; Asfandyar Mufti; Athina-Ioanna Daponte; Laetitia Teixeira; Anna Balato; Marco Romanelli; Francesca Prignano; Spyridon Gkalpakiotis; Curdin Conrad; Elizabeth Lazaridou; Natalia Rompoti; Marina Papoutsaki; Miguel Nogueira; Andrea Chiricozzi
Journal:  Am J Clin Dermatol       Date:  2022-08-17       Impact factor: 6.233

2.  Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis.

Authors:  Sohee Oh; Sungjun Choi; Hyun-Sun Yoon
Journal:  Ann Dermatol       Date:  2022-10       Impact factor: 0.722

3.  Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.

Authors:  Coco Dekkers; Mehran Alizadeh Aghdam; Marlies de Graaf; André C Knulst; Yolanda Meijer; Juul M P A van den Reek; Marike B Stadermann; Heike Röckmann
Journal:  Pediatr Allergy Immunol       Date:  2021-01-18       Impact factor: 6.377

4.  Systemic antipsoriatic treatment: do women respond better than men and if so, why?

Authors:  P Wolf
Journal:  Br J Dermatol       Date:  2021-10-07       Impact factor: 11.113

5.  Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Authors:  Ireny Y K Iskandar; Richard B Warren; Mark Lunt; Kayleigh J Mason; Ian Evans; Kathleen McElhone; Catherine H Smith; Nick J Reynolds; Darren M Ashcroft; Christopher E M Griffiths
Journal:  J Invest Dermatol       Date:  2017-12-06       Impact factor: 7.590

6.  Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis.

Authors:  Peter Takacs; Urja Lathia; Janey Shin; Francois Nantel
Journal:  Patient Prefer Adherence       Date:  2019-01-18       Impact factor: 2.711

7.  Predicting treatment success with biologics in psoriasis.

Authors:  J M P A van den Reek
Journal:  Br J Dermatol       Date:  2019-07-28       Impact factor: 9.302

8.  Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study.

Authors:  Christian Kromer; Dagmar Wilsmann-Theis; Sascha Gerdes; Sandra Philipp; Marthe-Lisa Schaarschmidt; Astrid Schmieder; Mohammed Dakna; Tobias Arnold; Wiebke Katharina Peitsch; Rotraut Mössner
Journal:  J Dtsch Dermatol Ges       Date:  2019-04-17       Impact factor: 5.584

9.  Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Authors:  Lotte S Spekhorst; Lieneke F M Ariëns; Jorien van der Schaft; Daphne S Bakker; Marijke Kamsteeg; Albert J Oosting; Ilona de Ridder; Annemiek Sloeserwij; Geertruida L E Romeijn; Marlies de Graaf; Inge Haeck; Judith L Thijs; Marie L A Schuttelaar; Marjolein S de Bruin-Weller
Journal:  Allergy       Date:  2020-05-05       Impact factor: 13.146

10.  Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.

Authors:  Andrew Blauvelt; Nianwen Shi; Russel Burge; William N Malatestinic; Chen-Yen Lin; Carolyn R Lew; Nicole M Zimmerman; Orin M Goldblum; Baojin Zhu; Mwangi J Murage
Journal:  Patient Prefer Adherence       Date:  2020-03-09       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.